Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiBlock
2024-515165-34-00Phase 3Completed
- Sponsor
- St. Olavs University Hospital
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Botulinum toxin type A arm with Placebo arm (2 arms). Primary endpoint: Change in mean monthly headache days. Started Jul 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2024-515165-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515165-34-00.